We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex Pharmaceuticals Shells Out $900 Million to Alter Deal With CRISPR Therapeutics
Vertex Pharmaceuticals Shells Out $900 Million to Alter Deal With CRISPR Therapeutics
Vertex Pharmaceuticals has paid $900 million to CRISPR Therapeutics, a Swiss-American biotech, to amend their collaborative agreement, entitling Vertex to more than half of the profits from future sales of CTX001, their investigational gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).